PPARG and Parkinson disease: As a PPARγ agonist, rosiglitazone’s protective effects against PD can be ascribed to its ability to modify microglial polarization through the upregulation of anti-inflammatory cytokines associated with the M2 phenotype, while concurrently downregulating pro-inflammatory cytokines associated with the M1 phenotype [196].